Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of Chemotherapy Induced Nausea and Vomiting Companies are:
Request for Free Sample Page: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
DelveInsight’s Chemotherapy Induced Nausea and Vomiting report covers around 15+ products under different phases of clinical development like:
Some of Chemotherapy Induced Nausea and Vomiting Therapies are:
Current Chemotherapy Induced Nausea and Vomiting Treatment Scenario and CINV Emerging Therapies:
Table of Contents:
Introduction
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
APD403: Acacia Pharma
Early Stage Products (Phase I)
CAM2047: Camurus
Preclinical and Discovery Stage Products
TA-A002: TALLC Corporation
Inactive Products
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight